Your session is about to expire
← Back to Search
Monoclonal Antibodies
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
Phase 1
Waitlist Available
Research Sponsored by ImmuneOncia Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing IMC-002, a new drug, in adults with advanced or recurring cancers. Researchers aim to understand how the drug works in the body and its effects on cancer.
Eligible Conditions
- Solid Tumors
- Lymphoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: IMC-002Experimental Treatment1 Intervention
Dose escalation will follow the traditional 3+3 design.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IMC-002
2020
Completed Phase 1
~20
Find a Location
Who is running the clinical trial?
ImmuneOncia Therapeutics Inc.Lead Sponsor
4 Previous Clinical Trials
117 Total Patients Enrolled
1 Trials studying Lymphoma
23 Patients Enrolled for Lymphoma
HEUNG TAE KIMStudy DirectorImmuneOncia Therapeutics Inc.
Ji Hye LeeStudy DirectorImmuneOncia Therapeutics Inc.
1 Previous Clinical Trials
23 Total Patients Enrolled
1 Trials studying Lymphoma
23 Patients Enrolled for Lymphoma